This page contains novel non-obvious combination therapy ideas that exploit orthogonal mechanisms for neurodegenerative diseases.
Score: 75/100 (N:8, M:8, R:7, D:7, S:7, C:8, B:7, K:7, X:8, P:8)
Combine astrocyte-mediated mitochondrial transfer enhancement with metabolic copacking strategies to deliver multi-component metabolic support to neurons[1][2]. This addresses the fundamental energy crisis in neurodegenerative diseases by both increasing the supply (mitochondrial transfer) and improving the packaging/utilization of metabolic substrates.
Mitochondrial Transfer Enhancement: Astrocytes transfer healthy mitochondria to stressed neurons via tunneling nanotubes. Enhance this natural process with:
Metabolic Copacking: Deliver metabolic substrates in optimized formulations:
In Alzheimer's disease, neuronal hypometabolism precedes clinical symptoms by decades[3]. In Parkinson's disease, complex I deficiency drives alpha-synuclein aggregation[4]. This combination attacks both the symptom (energy failure) and the cause (impaired mitochondrial quality control).
Score: 73/100 (N:7, M:9, R:8, D:6, S:7, C:9, B:6, K:7, X:9, P:7)
Combine TFEB-mediated lysosomal autophagy activation with proteasome enhancement to achieve dual clearance of pathological proteins[5][6]. Many neurodegenerative diseases involve both autophagic and proteasomal dysfunction.
TFEB Activation (see TFEB activator therapies):
Proteasome Enhancement:
Alpha-synuclein pathology involves both autophagic overload and proteasomal impairment[7]. Tau aggregates are cleared by both pathways depending on aggregation state. Dual activation ensures comprehensive protein homeostasis restoration.
Score: 72/100 (N:7, M:8, R:7, D:8, S:8, C:7, B:8, K:8, X:7, P:7)
Combine sleep-dependent glymphatic clearance enhancement with circadian rhythm optimization to maximize nighttime waste removal and normalize diurnal biological rhythms disrupted in neurodegeneration[8][9].
Glymphatic Enhancement:
Circadian Modulation (see melatonin for tauopathy):
In PSP and CBS, sleep architecture is severely disrupted, accelerating pathological protein accumulation. The glymphatic system operates primarily during NREM slow-wave sleep[10]. This combination optimizes the timing and efficiency of waste clearance.
Score: 71/100 (N:8, M:8, R:7, D:6, S:6, C:8, B:7, K:7, X:8, P:8)
Combine TREM2 microglial activation with epigenetic reprogramming of myeloid cells to achieve sustained neuroprotective phenotype switching[11][12]. Addresses both acute activation and long-term reprogramming of the neuroimmune response.
TREM2 Activation:
Epigenetic Reprogramming:
TREM2 variants are major genetic risk factors for Alzheimer's disease[13]. TREM2 activation promotes microglial phagocytosis but chronic activation leads to burnout. Epigenetic reprogramming converts pro-inflammatory microglia to a sustained disease-associated microglia (DAM) phenotype without exhaustion.
Score: 70/100 (N:8, M:8, R:7, D:6, S:7, C:8, B:6, K:7, X:8, P:7)
Combine anti-aggregation strategies that block alpha-synuclein seeding with proteostasis network restoration to prevent new seed formation while clearing existing aggregates[14][15].
Seeding Blockade:
Proteostasis Restoration (see nuclear factor erythroid 2-related factor 2):
Alpha-synuclein propagation follows a prion-like seeding mechanism[16]. Blocking seeds prevents new pathology while proteostasis restoration clears existing aggregates. This two-pronged approach addresses both the "infectious" spread and the accumulated burden.
This page serves as a pairing engine for combination therapy ideas. Each row suggests
modality pairings with rationale. For each combination:
For the highest-potential pairings identified above:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 6/10/10 | Combination therapy is well-established; logic-based design is emerging |
| Mechanistic Rationale | 8/10/10 | Rational design of synergistic combinations addresses multiple disease pathways |
| Addresses Root Cause | 8/10/10 | Multiple targets simultaneously; comprehensive disease modification |
| Delivery Feasibility | 5/10/10 | Multiple drugs increase complexity; pharmacokinetics challenging |
| Safety Plausibility | 5/10/10 | Drug-drug interactions; increased adverse event risk |
| Combinability | 9/10/10 | Foundation of the approach; built-in combinability |
| Biomarker Availability | 6/10/10 | Multiple biomarkers needed for each component |
| De-risking Path | 6/10/10 | Requires large trials; regulatory complexity |
| Multi-disease Potential | 7/10/10 | Broad applicability; customizable per disease |
| Patient Impact | 8/10/10 | Highest potential for disease modification |
| Total | 68/100 |
Davis CH, et al. Transcellular transfer of mitochondria. Nature Communications. 2014. ↩︎
Hayakawa K, et al. Astrocytic mitochondrial transfer. Neuron. 2016. ↩︎
Cunnane SC, et al. Brain energy metabolism. Journal of Alzheimer's Disease. 2013. ↩︎
Schapira AH, et al. Mitochondrial complex I deficiency. Lancet. 1989. ↩︎
Sardiello M, et al. A gene network regulating lysosomal biogenesis. Science. 2009. ↩︎
Wang Y, et al. TFEB and autophagy in neurodegenerative diseases. Molecular Neurobiology. 2016. ↩︎
Xilouri M, et al. Autophagy and alpha-synuclein. Journal of Molecular Neuroscience. 2013. ↩︎
Iliff JJ, et al. Glymphatic system. Journal of Clinical Investigation. 2013. ↩︎
Xie L, et al. Sleep drives metabolite clearance. Science. 2013. ↩︎
Nedergaard M, et al. Cleaning the brain. Scientific American. 2011. ↩︎
Wang Y, et al. TREM2 in Alzheimer's disease. Neuron. 2015. ↩︎
Gratuze M, et al. TREM2 and microglia in Alzheimer's disease. Journal of Experimental Medicine. 2018. ↩︎
Jonsson T, et al. TREM2 variant in Alzheimer's disease. New England Journal of Medicine. 2013. ↩︎
Brundin P, et al. Prion-like propagation of alpha-synuclein. Journal of Parkinson's Disease. 2017. ↩︎
Fink AL. The aggregation of alpha-synuclein. Accounts of Chemical Research. 2006. ↩︎
Peng C, et al. Cellular and regional vulnerability in alpha-synuclein propagation. Acta Neuropathologica. 2018. ↩︎